

December 4-7, 2014
Turnberry Isle Hotel, Aventura, Florida

Registration Information

Sponsored by American Academy of Addiction Psychiatry

Funding for this conference was made possible (in part) by 5R13DA015108 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

AAAP Board of Directors

Laurence M. Westreich, MD President

John A. Renner, Jr., MD President-Elect

Shelly F. Greenfield, MD, MPH Vice President

Kevin Sevarino, MD, PhD Treasurer

Larissa Mooney, MD Secretary

John J. Mariani, MD Member-at-Large

Frances R. Levin, MD Immediate Past President

Joseph Liberto, MD Chair, Past Presidents' Council

Ismene L. Petrakis, MD Chair, Area Directors

Jeffrey DeVido, MD Chair, Education Section

Richard N. Rosenthal, MD Chair, Public Policy Section

Maria Sullivan, MD, PhD Chair, Research Section

Karen Drexler, MD Chair, Treatment Section

Thomas Kosten, MD Editor-in-Chief The American Journal on Addictions

Rebecca Payne, MD Chair, Membership Committee

Timothy W. Fong, MD Chair, Program and Scientific Committee

Michelle Lofwall, MD Newsletter Editor, AAAP News

Robert P. Milin, MD International Representative

Dean Krahn, MD Chair, Professional Development Committee

What is AAAP?

The American Academy of Addiction Psychiatry (AAAP) is an academic professional membership organization founded in 1985 with over 1,000 members in the United States and around the world. The membership consists of psychiatrists who treat patients with addictive disorders, faculty at academic institutions engaged in psychiatry research and teaching, medical students, residents, fellows, and other health professionals making a contribution to the field of Addiction Psychiatry.

AAAP Mission Statement

- Promote high quality evidence-based screening, assessment and treatment for substance use and co-occurring mental disorders.
- Translate and disseminate evidence-based research to clinical practice and public policy.
- Strengthen Addiction Psychiatry specialty training and foster careers in Addiction Psychiatry.
- Provide evidence-based addiction education to health care trainees and health professionals to enhance patient care and promote recovery.
- Educate the public and influence public policy for the safe and humane treatment of those with substance use disorders.
- Promote prevention and enhance addiction treatment and recovery across the life span.
- Promote research on the etiology, prevention, identification and treatment of substance use and related disorders.

25th Annual Meeting and Symposium

AAAP's 25th Annual Meeting and Symposium will be held December 4-7, 2014 at the Turnberry Isle Hotel in Aventura, Florida. This event provides the latest scientific developments in Addiction Psychiatry and Addiction Medicine to physicians and allied health professionals who treat patients with substance use and mental health disorders. Meeting highlights include: Symposia, Workshops, Poster Sessions showcasing new research in the field, Breakfast for Trainees, Dessert with the Experts, Poster Luncheons, and a Case Conference.

Staff

Kathryn Cates-Wessel **Executive Director**

Miriam Giles

Director of Professional Development and Continuing Medical Education

Joe Barboza

Director of Finance, Grants Administration and Compliance

Isabel Vieira

Director of Education and **Program Development**

Lulu Malko Membership and **Outreach Coordinator**

Justina Andonian Project Coordinator, PCSS-O Blair Dutra

Project Coordinator, PCSS-MAT

Seth Acton

Data and Training Coordinator

PCSS-MAT

Coreen Domingo, DrPH

Associate Fditor

The American Journal on Addictions

Katherine Caine Research Assistant

Rhowen Giustibelli Research Assistant

Olivia Ruggiero Research Assistant

AAAP Annual Meeting CME Information

December 4-7, 2014

AAAP 25th Annual Meeting and Symposium Learning Objectives

At the conclusion of this conference participants will be able to:

- 1. Identify and diagnose substance use disorders and co-occurring mental disorders in clinical populations.
- 2. Utilize and promote evidence-based approaches for clinical treatment of substance abuse disorders and co-occurring mental disorders.
- 3. Employ established treatment guidelines to develop biopsychosocial treatment plans for patients with substance use disorders, including those with co-occurring mental disorders.
- 4. Demonstrate the use of evidence-based approaches and treatments to trainees.

Accreditation

American Academy of Addiction Psychiatry is accredited by the ACCME to provide continuing medical education for physicians.

Physicians and Nurse Practitioners Credit Designation

American Academy of Addiction Psychiatry designates this live activity for a maximum of 25.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Accreditation

The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 25.5 hours of Category 1 credit for completing this program.

Nurses Accreditation

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by American Academy of Addiction Psychiatry, an ACCME-accredited provider.

Other Professionals

Please contact the AAAP for other credit designation approvals at (401) 524-3076 or contact us at cmecpd@aaap.org.

Disclosure

In accordance with ACCME Essentials and Standards, anyone involved in planning or presenting this educational activity is required to disclose any relevant financial relationships with an ACCME defined commercial interest to the CME provider and the audience. Speakers who incorporate information about off-label or investigational use of drugs or devices will inform the audience. This information will be made available to participants at the beginning of the activity.

Program and Scientific Committee

Chair: Timothy W. Fong, MD Co-Chair: Robert T. Milin MD, FRCPC, DABPN

Elie Aoun, MD Steven L. Batki, MD Andrea Brandon, MD Eric D. Collins, MD

Wilson M. Compton, II, MD Michael A. Dawes, MD Nitigna V. Desai, MD Karen Drexler, MD

Inbal Gafni, MSc, MD, FRCPC

Marc Galanter, MD Amy L. Harrington, MD Christopher Holden, MD Thomas E. Kuich, MD William B. Lawson, MD, PhD Frances R. Levin, MD

Carla Marienfeld, MD

Peter R. Martin, MD

Andrea Maxwell, MD

Laura F. McNicholas, MD, PhD

Robert T. Milin, MD Edward V. Nunes, MD Ismene L. Petrakis, MD Ricardo Restrepo, MD, MPH

Richard K. Ries, MD Michael M. Scimeca, MD Ximena Sanchez-Samper, MD Kevin Sevarino, MD, PhD Susan M. Stine, MD, PhD

Jose Vito, MD Carol Weiss, MD

Laurence Westreich, MD Mark L. Willenbring, MD Penelope P. Ziegler, MD

Wednesday, December 3, 2014 Pre-Conference Addictions and Their Treatment

7:00 am - 8:00 am
8:00 am - 6:30 pm
2:00 pm - 4:00 pm
4:00 pm - 6:00 pm
Addictions and Their Treatment - Registration (separate registration is required)
Addictions and Their Treatment - (Part 1)
PCSS-MAT Steering Committee Meeting
PCSS-O Steering Committee Meeting

Thursday, December 4, 2014

8:00 am - 6:45 pm Addictions and Their Treatment - (Part 2) 8:00 am - 2:00 pm Board of Directors' Meeting 12:00 pm - 7:00 pm Registration Desk Open 1:00 pm - 2:00 pm **Public Policy Committee Meeting** 12:00 pm - 3:00 pm 2:00 pm - 4:00 pm Exhibit Set Up Symposium I: Pharmacogenetically Driven Treatments for Drug and Alcohol Dependence 3:00 pm - 6:00 pm **Exhibit Hall Open** 4:00 pm - 5:30 pm Concurrent Workshop Session A (1-5) 5:30 pm - 6:30 pm Welcome Reception - Highlighting new members and trainees 6:30 pm - 8:00 pm **Trainee Workshop** 8:00 pm - 9:00 pm **Recovery Meeting**

Friday, December 5, 2014

7:00 am - 8:00 am Breakfast for Trainees 7:00 am - 8:00 am Committee Meetings (Controversial Issues, MOC/EBT/Publications, The American Journal on Addictions) 7:30 am - 6:00 pm Registration Desk Open 7:00 am - 10:00 am Addictions and Their Treatment - (Part 3) 8:00 am - 5:00 pm Exhibit Hall Open 8:00 am - 9:00 am Keynote Session: Founder's Award 9:00 am - 10:00 am **Annual Business Meeting** 10:15 am - 11:45 am Concurrent Workshop Session B (1-5) 12:00 pm - 1:00 pm 12:00 pm - 1:00 pm 1:00 pm - 3:00 pm Poster Luncheon A Membership Committee Meeting Symposium II: What is the Evidence of Harm to Adolescents Using Cannabis? A Critical Review of the Data 3:00 pm - 4:30 pm Case Conference 4:30 pm - 5:00 pm Area Directors Meeting 5:00 pm - 6:00 pm Area Meetings 6:00 pm - 7:00 pm Auction/Reception 8:00 pm - 10:30 pm Film Workshop 10:30 pm - 11:30 pm **Recovery Meeting**

Saturday, December 6, 2014

6:30 am - 8:00 am **Education Committee Meeting** 7:00 am - 5:00 pm Registration Desk Open 7:00 am - 8:00 am Committee Meetings (Youth and Adolescent, Twelve-Step, Physician Health, Research) 8:00 am - 10:00 am Symposium III: Electronic Cigarettes: Friend, Foe, or Uneasy Ally to the Addiction Psychiatrist 10:15 am - 11:45 am Concurrent Workshop Session C (1-5) 12:00 pm - 1:00 pm Poster Luncheon B 1:00 pm - 2:30 pm **Paper Session** 2:30 pm - 3:30 pm Dessert with the Experts (Small Group Discussions with Experts in the Field) 3:30 pm - 4::30 pm Poster Session (not accredited for CME) 3:30 pm - 5:30 pm **MOC Workshop** 7:00 pm - 9:00 pm Gala Event and Awards Ceremony 9:00 pm - 10:00 pm **Recovery Meeting**

Sunday, December 7, 2014

7:00 am – 11:00 am	Registration Desk Open
7:00 am - 8:00 am	Program and Scientific Committee Meeting
8:00 am - 9:00 am	Medical Update: Traumatic Brain Injury, Substance Misuse and Substance Use Disorders
9:00 am - 11:00 am	Symposium IV: Cocaine and Stimulant Dependence: New Strategies for an Old Problem
11:00 am	Conference Adjourns

2014 Conference Highlights

Symposium I: Pharmacogenetically Driven Treatments for Drug and Alcohol Dependence

Symposium Chair: Albert Arias, MD, Yale University School of Medicine, Henry Kranzler, MD, University of Pennsylvania, Perelman School of Medicine, David Oslin, MD, University of Pennsylvania; and Thomas Kosten, MD, Baylor College of Medicine

This symposium will feature three presenters who will review the state of the art clinically relevant pharmacogenetics of substance use disorder treatments. The speakers will focus on reporting cutting edge findings from clinical trials with an emphasis on pharmacogenetics of alcoholism and cocaine dependence treatment response.

Dr. Kranzler will review original research findings from his trials of naltrexone, sertraline, and topiramate treatment of alcoholism. Dr. Oslin will present findings from his line of research on naltrexone phamacogenetics in alcoholics. Dr. Kosten will review findings from pharmacogenetic analyses of disulfiram and immunologic based treatment trials for cocaine dependence.

The symposium will educate AAAP members on cutting edge pharmacogenetic findings, and help to fill in the knowledge gap for providers on this exciting emerging area of personalized medicine. It is becoming increasingly clear that pharmacogenetics is clinically relevant, and providers will need to learn and understand this area of research in order to help optimize treatment outcomes for their patients. This highly significant symposium will influence clinical practice, research, and will provide important education on emerging treatment modalities. It may also potentially influence policy. All of the speakers are leaders in the field. Each presenter will speak for 30 minutes, and 30 minutes total will be spent on discussion or answering audience questions.

At the conclusion of this activity participants will be able to:

- 1. Describe the latest findings with regard to naltrexone pharmacogenetics and alcoholism treatment
- 2. Describe the impact of variation in kainate receptor subunit genes and topiramate response in AUDs
- 3. Identify genetic moderators of biological therapies for cocaine dependence

Source of Funding: None

Symposium II: What is the Evidence of Harm to Adolescents Using Cannabis? A Critical Review of the Data

Symposium Chair: David Atkinson, MD, Assistant Professor at University of Texas-Southwestern; Christopher Hammond, MD, Solnit Integrated Program Yale Child Study Center; Kevin Gray, MD, Medical University of South Carolina; Scott Krakower, DO, Zucker Hillside Hospital; and Greg Tau, MD, PhD, Columbia University

Cannabis has gained unprecedented national attention in the media over the past several years, and scientific evidence has substantially grown over that time. A knowledge gap currently exists regarding the evidence of harm to adolescent users. Adolescent Perception of harm has decreased greatly since 2008 with only 40% of 12th graders seeing "great risk" in using regularly. While fraught with difficult questions around extracting correlation from causality, the literature provides guidance on specific potential harms. Basic science, longitudinal, population-based, and twin studies have all demonstrated potential harms of adolescent cannabis use that remain significant when controlling for potentially confounding variables. This proposed scientific literature review and appraisal will help participants review, analyze, and contextualize the evidence of harm for adolescent cannabis users.

Dr. Atkinson will review the literature regarding the evidence of cannabis as an addictive substance, while reviewing the neurobiology of addiction, focusing on the specific involvement of cannabis. Attention will be given to the socio-economic sequelae of addiction. Dr. Hammond will review the evidence examining links between cannabis use and mood disorders (depression and bipolar) and anxiety disorders. Dr. Krakower will review the evidence regarding cannabis's effects on the development of psychosis during acute use, including clinical laboratory studies, and he will review prospective and epidemiologic data on the link between schizophrenia and adolescent cannabis use. Dr. Tau will review the evidence on cannabis on cognition, including studies of IQ and studies reviewing different Research Domain Criteria. As discussant, Dr. Gray will review the discussion and provide insights into the relative significance of the various findings presented for the everyday clinician.

At the conclusion of this activity participants will be able to:

- 1. Review and understand the evidence regarding harm for adolescents using cannabis
- 2. Analyze the current data in light of its current limitations
- 3. Apply this knowledge to further research work and clinical care

Source of Funding: None

Symposium III: Electronic Cigarettes: Friend, Foe, or Uneasy Ally to the Addiction Psychiatrist?

Symposium Chair: Mary F. Brunette, MD, Geisel School of Medicine at Dartmouth; James Sargent, MD, Geisel School of Medicine at Dartmouth; and Gregory Connolly, DMD, MPH, Harvard School of Public Health

Since they became available in 2008, the use of electronic cigarettes (e-cigarettes) has been dramatically rising in the U.S. These devices heat a nicotine solution to create inhalable nicotine vapor. As of 2012, 8% of the general population and 30% of smokers had tried them. Completely unregulated by any agency, their safety and impact on nicotine addiction is largely unknown. The presenters of this symposium will provide a comprehensive overview of e-cigarette technology, the extent of their use in the U.S., and examples of how e-cigarette use may impact vulnerable populations.

First, Dr. Connolly will describe e-cigarette design and constituents as well innovations, including chemosensory agents that optimize nicotine delivery, provide cues for reward, and reduce withdrawal as well as new microchip technology that may enhance abuse liability. Second, Dr. Sargent will discuss e-cigarette use among youth and young adults. He will present data from a 2013 national American sample demonstrating rising e-cigarette use with and without other tobacco products among young people. Third, Dr. Brunette will discuss the prevalence of tobacco product use among people with mental illness and with addiction. She will present recent data e-cigarette use among Medicaid recipients with mental illnesses and describe short term impact of e-cigarette use among persistent smokers with severe mental illness who have been unable to quit combustible tobacco products. During the discussion period, the speakers will engage the audience with a discussion regarding the potential utilities and liabilities of these controversial devices.

At the conclusion of this activity participants will be able to:

- 1. Describe how electronic cigarettes work
- 2. Discuss the clinical correlates, risks and benefits of elect
- 3. Recommend alternatives to electronic cigarette use

Source of Funding: None

Symposium IV: Cocaine and Stimulant Dependence: New Strategies for an Old Problem

Symposium Chair: Edward Nunes, MD, Columbia University/NYS Psychiatric Institute; Andrew Saxon, MD, University of Washington; Theresa Winhusen, PhD, University of Cincinnati College of Medicine; and Madhukar Trivedi, MD, University of Texas Medical Center

Dependence on cocaine and stimulants (mainly methamphetamine) remain widespread, serious public health problems. Behavioral treatments (e.g. Cognitive Behavioral Relapse Prevention, Contingency Management, 12-Step Facilitation) have demonstrated effectiveness in controlled trials. However, a substantial proportion of cocaine/stimulant dependent patients fail to respond to behavioral treatments, and the goal of developing medication treatments has remained elusive. This symposium will present primary outcome data from recently completed clinical trials from the NIDA Clinical Trials Network (CTN) that have tested "outside the box" strategies for cocaine/stimulant dependence, namely: 1) Aerobic exercise; 2) Treating co-occurring nicotine dependence; 3) The opioid partial agonist and putative kappa antagonist buprenorphine; 4) The 5HT-1A partial agonist and putative D4 antagonist buspirone. Discussion will focus on what we can learn from these trials about the management of cocaine/stimulant dependent patients who fail to respond to standard behavioral therapies.

At the conclusion of this activity participants will be able to:

- 1. Recognize effective behavioral treatments for cocaine/stimulant dependence, and their limitations, namely the substantial rate of non-response
- 2. Discuss recent therapeutic strategies tested for cocaine/stimulant dependence, their rationales, and findings from clinical trials
- 3. Apply this knowledge to the development of treatment strategies for individual patients, particularly those who do not respond readily to initial behavioral treatments.

Source of Funding: NIDA U10DA020024, 5U10DA013714, U10DA01373, U10DA013035, K24DA022412

Medical Update: Traumatic Brain Injury, Substance Misuse and Substance Use Disorders

Presenter: John D. Corrigan, PhD, Professor, The Ohio State University

This presentation will describe the nature and extent to which traumatic brain injury (TBI) co-occurs with substance misuse and substance use disorders. A theoretical model for conceptualizing opportunities for intervention will be presented and unique characteristics of treatment will be discussed.

At the end of the symposium participants will be able to:

- 1. Describe the extent of co-occurring TBI with substance misuse and substance use disorders
- 2. List sources of increased morbidity
- 3. Discuss opportunities for intervention

Source of Funding: None

Area Meetings Luncheon

The Area Meetings provide an opportunity to meet with colleagues in your geographic region to discuss current issues and activities impacting your work and opportunities for collaborating.

Case Conference

Chair, Moderator: Michael M. Scimeca, MD; Fellow AJ Manett, MD; Clinicians: Steven L. Batki, MD and Kyle Kampman, MD

The case conference provides an opportunity to learn, teach and share clinical experiences. A Fellow briefly presents a problematic treatment case. Two noted clinicians discuss the case presenting their personal clinical approaches: sharing their therapeutic styles and thinking. This approach focuses on stimulating the audience to actively participate with their own case vignettes, opinions, reactions and provocative questions.

Mentor Program

The Annual Meeting mentor program will match senior colleagues with new members, residents and medical students. Scheduled activities include the Breakfast for Trainees which provide opportunities for new and/or prospective members to learn about the field and AAAP's mission. If you are interested in serving as a mentor or mentee at the Annual Meeting, please indicate when registering.

Follow us on Twitter @AAAP1985 and tweet about the Annual Meeting using hashtag #AAAPAnnualMeeting2014

Addictions and Their Treatment

(formerly known as AAAP Review Course)

Wednesday, December 3, 8:00 am - 6:30 pm Thursday, December 4, 8:00 am - 6:45 pm Friday , December 5, 7:00 am - 10:00 am

Who Should Attend?

AAAP's Addictions and Their Treatment course helps psychiatrists prepare for American Board of Psychiatry and Neurology (APBN) examination for subspecialty certification and recertification in Addiction Psychiatry. The course is recommended for all residents and periodically for all academic and treatment personnel to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners.

Both General Psychiatry and Addiction Psychiatry require knowledge of Addiction Psychiatry/Medicine. The expanded (20 hours) Addictions and Their Treatment course will assist diplomates as they prepare for their Maintenance of Certification (MOC) requirements and/or to anyone preparing for an ABPN Board Examination.

Are You an AAAP Member Who Needs to Fulfill MOC Requirements?

AAAP will continue to develop CME activities to assist AAAP Members meet their MOC requirements.

Course Director

Kevin Sevarino, MD, PhD, Medical Director, Newington Mental Health Firm, Connecticut V.A. Healthcare System, Assistant Clinical Professor, Yale University School of Medicine and University of Connecticut School of Medicine Co-Director: Joji Suzuki MD, Director, Division of Addiction Psychiatry, Brigham and Women's Hospital, Instructor in Psychiatry, Harvard Medical School

Topics Include:

- General Concepts
- Psychosocial Treatments
- Non-Substance-Based Addictions
- Forensic Issues in Addiction
- Club Drugs
- Dual Diagnosis Affective and **Anxiety Disorders**
- Personality Disorders and Psychosis
- Neurobiology/Genetics
- Substance Use Disorders in Adults and Transitional Youth with ADHD
- ◆ Tobacco Use Disorders and Smoking Cessation ◆ Alcohol Use Disorders
- Screen/Brief Intervention and Prevention
- Medical Comorbidities
- Sedative/Hypnotic Addictions

- Opioid Use Disorders
- Adolescent Addiction
- Special Populations
- Psychostimulant Use Disorders
- Pain and Addiction
- Cannabis

Course Materials

The registration fee includes a syllabus that contains a copy of the slides with accompanying text, bibliographical information, and sample exam questions. The Addictions and Their Treatment materials will be available to purchase after the course.

Questions? Email addictions@aaap.org.

Please check the appropriate box on the registration form if you plan to attend or register online by visiting www.aaap.org

You will receive a discount on the Addictions and Their Treatment registration fee if you also register for the Annual Meeting.

AAAP Addictions and Their Treatment

Wednesday, December 3, 2014

Learning Objectives

At the conclusion of this course participants will be able to:

- 1. Describe new advances in the pharmacotherapy and psychotherapy of alcohol, cocaine, opioid and nicotine addictive disorders.
- 2. Discuss the epidemiology of substance use disorders and their co-occurrence with other mental disorders and review current recommended approaches for concurrent treatment of substance use disorders and other mental health disorders.
- 3. Describe the role of genetics in the risk for developing alcohol and drug use disorders.
- 4. Identify the major neurobiological pathways involved in addictive disorders.
- 5. Identify the molecular mechanisms that are altered following drug and alcohol use.
- 6. Review the literature on screening and brief intervention effectiveness, and apply this technique to your practice. .
- 7. Review current treatment guidelines and how to utilize them in clinical practice.

Accreditation

American Academy of Addiction Psychiatry is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

American Academy of Addiction designates this live activity for a maximum of 20 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Accreditation

The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 20 hours of Category 1 credit for completing this program.

If You are an AAAP Member, claim Self-Assessment Credits from this Live Course

The American Board of Psychiatry and Neurology has approved AAAP's Addictions and Their Treatment course for AAAP Members to receive 20 CME credits – 12 CME credits from the educational activity plus 8 CME credits towards MOC Self-Assessment credit.

Disclosure

In accordance with ACCME Essentials and Standards, anyone involved in planning or presenting this educational activity is required to disclose any relevant financial relationships with commercial interests in the healthcare industry. This information will be made available to participants at the beginning of the activity. Speakers who incorporate information about off-label or investigational use of drugs or devices will be asked to disclose that information at the beginning of their presentation.

Need to Meet MOC Requirements?

AAAP Members registering for the Annual Meeting can select to participate in unique Maintenance of Certification (MOC) opportunities in conjunction with AAAP's Annual Meeting and Symposium!

AAAP Members who register to attend AAAP's Annual Meeting and Symposium will be asked to select free access to complete ONE of the following AAAP ABPN Approved MOC products: Either AAAP's 2012 Self-Assessment Examination OR AAAP's 2013 Self-Assessment Examination OR AAAP's PIP "Improving Patient-Centered Outcomes in Treating Patients with Substance Use Disorders Who Are Also Tobacco Users." AAAP Members can participate in one of these activities anytime between November 10 - December 10, 2014, after which the activities will be closed. During this time, AAAP Members will complete the activities, receive AMA PRA Category 1 CME creditTM. AAAP Members may use the selected activity to identify areas where they may need to improve their knowledge. At the meeting they can select to attend sessions that will help them "brush up" on their knowledge and areas they've identified gaps in competencies.

AAAP Members registering for the Addictions and Their Treatment course can receive up to 8 Self-Assessment credits in conjunction with the course!

AAAP Members who register to attend AAAP's *Addictions and Their Treatment* course can earn 12 CME credits from the educational activity plus 8 CME credits from a Self-Assessment activity. Using an interactive audience response system, test your knowledge during *Addictions and Their Treatment* live sessions. Expert clinicians, who serve as faculty for the Addictions course, will lead lively multiple choice question and answer sessions before their presentation. Participants answer multiple choice questions using an interactive audience response system, which instantly presents the audience responses on the screen, allowing private comparison to others in the audience.

Questions will cover clinical knowledge important to practicing psychiatrists, including diagnosis, treatment, and new developments.

Continue to visit www.aaap.org for the most up to date information on the Annual Meeting and Addictions and Their Treatment course!



AAAP 25th Annual Meeting Registration Form

December 4-7, 2014

By becoming a AAAP Member, you will receive substantial savings on your Annual Meeting registration rates and will be offered MOC Products Free of Charge!

(please	e print)	(First)		(La	ıst)			(Degree))
Title:		0	Organization/Co	mpany :					
Mailiı	ng Ad	dress:							
City:		s	tate/Province: _			Country:	Zi	ipcode:	
Work	Phon	e: ()						-	
Fax: ()			ı	Email address:			
Gend	er:	☐ Male	☐ Fen	nale					
Ethnicity:		American Indian or A Native Hawaiian or or Other		er 🔲		n anic or Latino	_	Black or African Ar White	merican
		Please check this box if you re AAAP will contact you for furt	her details before	the conference	ence.				eds.
		AAAP will be providing a list on Please check this box if you do	of attendees inclu o <u>not</u> want to be i	ding contac ncluded on	t infor this lis	mation to all mee t.	eting at	tendees.	
Pleas	e indi	cate your AAAP Membership S	itatus:			🗖 ААА	P Mem	ber 🔲 Non-Me	ember
Are y	ou a n	ew AAAP Member (since Dece	mber 2013)?			Yes		☐ No	
Are y	ou a fi	rst time attendee to a AAAP A	nnual Meeting a	nd Sympo	sium?	Yes		☐ No	
Woul	d you	like to join AAAP and receive	a discount on me	eeting regi	stratio	n? 🔲 Yes		☐ No	
If "Yes	s," ple	ase visit www.aaap.org and cli	ck on "Member C	enter" to co	omple	te a membership	applic	ation online.	
		rgh the process of completing a Yes, I'd like to participate in this fi	ree workshop.	<u> </u>	-	-		this free worksho	p.
_		tion Fees (Please check all boxes	that apply)						
		eting Rates		_		d Their Treatmer			
	AP Me		\$515			er attending annu		•	\$600
_		Member	\$515			er not attending a		•	\$750
☐ Non-Member Physician			\$625 \$260			nber attending an nber not attending		•	\$500 \$650
Resident Student			\$200 \$25	_		n-member attend			\$660
		Health Professional	\$275	_ `		n-member attend	-	_	\$830
_		of AAAP Member*	\$240			:h professional	armaar meeting	\$750	
		of Non-Member*	\$265			nding annual mee	eting		\$350
Spouse Name*:				_ 🗖 Traine	Trainees not attending annual meeting				\$450
			TOTAL (include	e the total do	ollar ar	mount for all chec	ked box	res)	
		*Separate Registration is This regis	required for a Spous stration does not inc					rence functions.	
AAAP	Conf	erence Mentor/Mentee Progra	m (Please choose	one option	- eithe	er Mentor or Ment	tee)		
□ ı	would	d like to serve as a mentor for	a:						
		_New AAAP Member	Res	ident		Med	dical St	udent	
$f \square$ I am a mentee and I would like to be assigned a mentor. I am a									
		_New AAAP Member	Res	ident		Med	dical St	udent	
						(regis	stration	n form continued o	on back)

AAAP 25th Annual Meeting Registration Form

December 4-7, 2014

Donation	Would you be willing to contribute \$25 to the Sheldon I. Miller Educational Fund to support trainee activities in the field of Addiction Psychiatry? Contributors will be acknowledged at the Annual Meeting.						
How did you	ı hear about the AAAP 25 th Annı	ual Meeting and S	Symposium?				
	AAAP Newsletter AAAP Website AAAP Email Blast AAAP Mailing	Advertisement (
Payment Me	ethod:						
	Check made payable to AAAP		Visa/MasterCard/American	Express			
Card Number	er:		Exp. Date:	Sec. Code			
Name on care	d:						
Authorized Si	gnature:						
Credit Card B	illing Address:						
City:	State/	Province:	Country:	Zip code :			
Phone: ()	Email add	ress:				
policy is sig	nber 1, 2014, 12 midnight (ET), no rened. ee to the cancellation policy noted		·				
Emergency	Contact Information						
	ne:		Emergency Contact Pho	ne: ()			
Registration can also be completed online at http://www.cvent.com/d/t4qqpn. Please detach this form and mail or fax to: American Academy of Addiction Psychiatry 400 Massasoit Avenue, Suite 307, East Providence, RI 02914 Phone: (401) 524-3076 ~ Fax: (401) 272-0922 Questions? Email: annualmeeting@aaap.org							
Hotel inforn	nation at the Turnberry Isle Hote	el, Aventura, Flori	da:				
The hotel c Hotel at 1-8 room reser reservation the Fort La	onference rate is \$195 per night for 388-539-7894. Please indicate you a vation and your credit card will be can be seen as than 30 days prior to your a uderdale Airport.	single/double occu re with AAAP to rec harged for one nig arrival date or else fo	upancy rooms. To reserve a room eive the conference rate. One ni ht's deposit upon making your ro orfeit 100% of your deposit. The	ght's deposit is required with your eservation. You must cancel your			
			Signature				